BERKELEY HEIGHTS, N.J., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq: EDGE) today announced financial results for the full-year ended December 31, 2018. Financial Results...
LONDON, Nov. 30, 2018 (GLOBE NEWSWIRE) -- In late November 2018, NetScientific (AIM: NSCI) announced that its portfolio company PDS Biotechnology and Edge Therapeutics (NASDAQ: EDGE) will...
-Merger would create publicly-traded immuno-oncology biotechnology company developing novel products for treating early- and late-stage cancer- -Growing product pipeline utilizing Versamune®, a...
BERKELEY HEIGHTS, N.J., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq: EDGE) today announced financial results for the quarter ended September 30, 2018. Third Quarter...
BERKELEY HEIGHTS, N.J., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE) today announced financial results for the quarter ended June 30, 2018. Second Quarter...
BERKELEY HEIGHTS, N.J., June 27, 2018 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE) today announced updated results from its ongoing analyses of the Phase 3 NEWTON 2 study of...
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Edge Therapeutics, Inc. (“Edge” or ''the Company'') (NASDAQ:...
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Edge Therapeutics, Inc. (“Edge” or ''the Company'') (NASDAQ:...
BERKELEY HEIGHTS, N.J., May 01, 2018 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE) today announced financial results for the quarter ended March 31, 2018. First Quarter...
BERKELEY HEIGHTS, N.J., April 30, 2018 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE) today announced that its Board of Directors is conducting a comprehensive review of strategic...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관